How many drugs treat hyperlipidemia?

Drug Landscape tracks 10 marketed treatments for hyperlipidemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hyperlipidemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

hyperlipidemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

hyperlipidemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating hyperlipidemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tryvio	APROCITENTAN	Idorsia	Endothelin Receptor Antagonist [EPC]		2025-01-01
olmesartan medoxomil-hydrochlorothiazide	OLMESARTAN	Cosette	Thiazide Diuretic [EPC]		2019-01-01
Vascepa	ICOSAPENT ETHYL	Amarin Pharms	icosapent ethyl	Diacylglycerol O-acyltransferase 1	2012-01-01
Trilipix	CHOLINE FENOFIBRATE	AbbVie	Peroxisome Proliferator Receptor alpha Agonist	Fatty acid-binding protein, intestinal	2008-01-01
Synthroid	levothyroxine	Generic (originally multiple — AbbVie/Synthroid)	Thyroid hormone	THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial	2002-08-13
Zetia	EZETIMIBE	Merck & Co.	HMG-CoA Reductase Inhibitor [EPC]	Niemann-Pick C1-like protein 1	2002-01-01
Unithroid	LEVOTHYROXINE SODIUM	Fresenius Kabi	l-Thyroxine	Thyroid hormone receptor beta	2000-01-01
Tricor (Micronized)	FENOFIBRATE	Salix	Peroxisome Proliferator Receptor alpha Agonist [EPC]	PPARα	1993-01-01
Mevacor	LOVASTATIN	Merck & Co.	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01
Colestid	Colestipol	Pfizer	Bile Acid Sequestrant		1977-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in hyperlipidemia
AbbVie · 2 drugs in hyperlipidemia
Merck & Co. · 2 drugs in hyperlipidemia
Bristol Myers · 1 drug in hyperlipidemia
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in hyperlipidemia
Cedars-Sinai Medical Center · 1 drug in hyperlipidemia
Cosette · 1 drug in hyperlipidemia
Direct_Rx · 1 drug in hyperlipidemia
Fresenius Kabi · 1 drug in hyperlipidemia
Generic (originally multiple — AbbVie/Synthroid) · 1 drug in hyperlipidemia
Idorsia · 1 drug in hyperlipidemia
MEDPOINTE PHARM HLC · 1 drug in hyperlipidemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in hyperlipidemia:

Cite this brief

Drug Landscape (2026). hyperlipidemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hyperlipidemia. Accessed 2026-06-10.

hyperlipidemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing